| Combination of | |
|---|---|
| Bupivacaine | Local anesthetic |
| Meloxicam | Nonsteroidal anti-inflammatory drug (NSAID) |
| Clinical data | |
| Trade names | Zynrelef |
| Other names | HTX-011 |
| License data | |
| Routes of administration | Intralesional,infiltration |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Bupivacaine/meloxicam, sold under the brand nameZynrelef, is afixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery.[1][2][4] It containsbupivacaine andmeloxicam.[1][2]
The most common side effects of bupivacaine/meloxicam are dizziness, constipation, vomiting, and headache.[1][2]
It was authorized for medical use in the European Union in September 2020,[2] and approved in the United States in May 2021.[1][5]
In the European Union, the combination bupivacaine/meloxicam is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.[2]
In the United States it is indicated for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty in adults.[1][5]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
